A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.
A preoperative trial shows that activating the progesterone receptor with low-dose megestrol can deepen estrogen blockade and curb tumor proliferation, without added toxicity, pointing to a simpler ...
The presence of the progesterone receptor marks this tumor as hormone-responsive and indicates that hormone therapy should be considered as a component of her adjuvant therapy. In some breast cancer ...
Stakeholder Perspectives on Provider-Initiated Clinical Breast Examination and Patient Navigation in Ethiopian General Hospitals: Situational Analysis for Implementation Study Biomarkers estrogen ...
In this segment, Dr. Gregory Vidal discusses the role of estrogen receptor antagonists in the treatment of ER-positive, HER2-negative metastatic breast cancer following progression on prior endocrine ...
Selpercatinib for tumors with RET fusions. Can hormone therapy be used to prevent breast cancer? Most early-stage breast cancers are ER-positive, and clinical trials have studied whether hormone ...
The transition to menopause is marked by a progressively higher density of estrogen receptors (ER) on brain cells, a measure that remains elevated in women up to their mid-sixties, according to a new ...
Researchers discovered a mechanism by which estrogen can trigger fast neuronal responses. Estrogen, the major female ovarian hormone, can trigger nerve impulses within milliseconds to regulate a ...
PET scans showing brain estrogen receptor (ER) density in a premenopausal (left) and a postmenopausal (right) woman. The color scale reflects brain ER density, with brighter colors indicating more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results